MedPlus Health Services has informed stock exchanges about a regulatory action affecting one of its subsidiary operations in Karnataka. The company disclosed that Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services, received a suspension order for a drug license at one of its retail locations.

Regulatory Action Details

The suspension order was issued by the Assistant Director of Drugs Control Administration, Gadag Circle, Karnataka, and was received by the company on January 2, 2026. The action specifically targets the store situated at KC Rani Road, Gadag, Karnataka, with the drug license suspended for a duration of one day.

Legal Framework and Violation

The suspension order was issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has disclosed this information in compliance with SEBI regulations, specifically under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The disclosure follows SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, which mandates companies to report such regulatory actions.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. The estimated revenue loss from the one-day suspension amounts to approximately ₹0.23 lacs for the affected store location.

Compliance and Disclosure

MedPlus Health Services has ensured proper disclosure of this regulatory development through multiple channels. The information has been made available on the company's official website at www.medplusindia.com , as well as on the websites of both stock exchanges - BSE Limited and National Stock Exchange of India Limited.

The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, demonstrating the company's commitment to maintaining transparency with stakeholders regarding regulatory matters affecting its subsidiary operations.

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, has received a suspension order for one of its drug licenses in Andhra Pradesh.

Regulatory Action Details

The suspension order was issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Vijayawada, Andhra Pradesh. The order specifically targets a store situated at Gollapudi One Center in Andhra Pradesh and was received on December 31, 2025.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. The seven-day suspension is expected to result in a potential revenue loss of approximately ₹2.10 lakhs for the affected store operations.

Regulatory Compliance

The disclosure was made under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company followed SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, for this disclosure.

The violation falls under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, though specific details of the contravention were not elaborated in the regulatory filing. The disclosure ensures transparency regarding regulatory actions that may impact the company's subsidiary operations and financial performance.